May 24, 2011 -- The shareholders meeting of Siegfried Holding AG approved all proposals put forward by the Board of Directors. Gilbert Achermann, Binningen, Reto Garzetti, Zurich, Dr. Beat In- Albon, Oberwil BL and Dr. Thomas Villiger, Muttenz were newly elected onto Siegfried’s Board. Gilbert Achermann will succeed Dr. Markus Altwegg as Chairman.
The term of office for Board members was reduced from three years to one year.
Rudolf Hanko, Siegfried’s CEO, confirmed the outlook for the 2011 financial year. As announced earlier, he expects both sales and profitability to rise. Moreover, he anticipates the implementa- tion of significant strategic projects during the current year.
For further information:
Peter Gehler, Head Corporate Center
peter.gehler@siegfried.ch
Tel. +41 (0)62 746 11 44
Mobile +41 (079) 416 41 16
Fax +41 (0)62 746 11 03
Siegfried Holding AG
Untere Brühlstrasse 4
CH-4800 Zofingen
Tel. +41 (0)62 746 11 11
Fax +41 (0)62 746 11 03
www.siegfried.ch
About Siegfried
Active in Life Science markets, the Siegfried Group is a global manufacturer of pharmaceutical products with produc- tion facilities located in Switzerland, Malta and the USA. At the end of 2010, Siegfried employed approximately 700 employees and achieved annual sales of CHF 314 million. Siegfried Holding AG is listed on the Swiss Exchange in Zurich (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding inter- mediate steps and standard products, and provides development and production services for drugs in finished dos- age forms.
